Segment information Segment information (Tables)

12 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Revenues

Revenues were as follows for the years ended December 31, 2013, 2012 and 2011 (in millions):

	2013		2012		2011
Product sales:
Neulasta®	$	4,392	$	4,092	$	3,952
NEUPOGEN®	1,398		1,260		1,260
ENBREL	4,551		4,236		3,701
Aranesp®	1,911		2,040		2,303
EPOGEN®	1,953		1,941		2,040
Sensipar®/Mimpara®	1,089		950		808
Vectibix®	389		359		322
Nplate®	427		368		297
XGEVA®	1,019		748		351
Prolia®	744		472		203
Kyprolis®	73		—		—
Other	246		173		58
Total product sales	18,192		16,639		15,295
Other revenues	484		626		287
Total revenues	$	18,676	$	17,265	$	15,582

Geographical information with respect to revenues and long-lived assets

Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment) was as follows (in millions):

	Years ended December 31,
	2013		2012		2011
Revenues:
United States	$	14,480	$	13,415	$	11,985
Rest of the world (ROW)	4,196		3,850		3,597
Total revenues	$	18,676	$	17,265	$	15,582

	December 31,
	2013		2012
Long-lived assets:
United States	$	2,772	$	2,906
Puerto Rico	1,822		1,908
ROW	755		512
Total long-lived assets	$	5,349	$	5,326

Revenues earned from major customers

Certain information with respect to these customers for the years ended December 31, 2013, 2012 and 2011, was as follows (dollar amounts in millions):

	2013			2012			2011
AmerisourceBergen Corporation:
Gross product sales	$	8,527		$	7,556		$	7,574
% of total gross revenues	35		%	34		%	36		%
% of U.S. gross product sales	44		%	43		%	45		%
McKesson Corporation:
Gross product sales	$	6,440		$	5,898		$	4,591
% of total gross revenues	27		%	27		%	22		%
% of U.S. gross product sales	32		%	32		%	27		%
Cardinal Health, Inc.:
Gross product sales	$	3,209		$	3,245		$	3,021
% of total gross revenues	13		%	15		%	14		%
% of U.S. gross product sales	17		%	19		%	18		%